Last reviewed · How we verify
Fludarabine (FLU)
Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.
Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Small lymphocytic lymphoma (SLL).
At a glance
| Generic name | Fludarabine (FLU) |
|---|---|
| Also known as | FLU, FaraA |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | Purine nucleoside analog |
| Target | Ribonucleotide reductase, DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Fludarabine is a fluorinated purine nucleoside analog that is phosphorylated intracellularly to its active form, fludarabine triphosphate. This active metabolite inhibits both ribonucleotide reductase and DNA polymerase, disrupting DNA synthesis and repair. The resulting DNA damage triggers apoptosis, particularly in lymphoid malignancies where cells have high proliferation rates and limited DNA repair capacity.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma
- Small lymphocytic lymphoma (SLL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Nausea and vomiting
- Fever
- Fatigue
- Neurotoxicity (confusion, peripheral neuropathy)
- Tumor lysis syndrome
Key clinical trials
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (PHASE1)
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (PHASE3)
- Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Natural Killer-cell Therapy for Acute Myeloid Leukemia (PHASE1, PHASE2)
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |